0IJO.LSE Exelixis, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
76.8x
P/B
-
ROE
46.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.

Is 0IJO.LSE undervalued?

Graham number

The Graham number of Exelixis, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Exelixis, Inc. fundamental analysis

No fundamental analysis for Exelixis, Inc. yet.

Exelixis, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibito…

Full company profile